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Abstract. Somatic mitochondrial DNA (mtDNA) mutations
have been found in a subset of endometrial cancers (EC) from
different populations. We have investigated the relationship
between mtDNA changes and clinical and pathological
variables of women affected by EC. mtDNA mutations were
detected both in early (3/32; 9%) and in advanced (1/8;
12%) stages of uterine tumors. However, patients carrying
the mtDNA mutations or the normal mtDNA sequence had
indistinguishable clinicopathological data, including age,
clinical stage, histological grade and type or depth of myo-
metrial invasion. It is noteworthy that mtDNA mutations
were not detected in hyperplastic endometrial tissues or in
ECs coexisting with hyperplasia, nor in a single case of
endometrial stromal sarcoma. LOH at the tumor suppressor
genes RB1 and TP53 as well as p16INK4A alterations (LOH,
gene deletion) were found in tumors carrying mtDNA
mutations. These results suggest that somatic mtDNA
mutations are detected in a subset of ECs, although they are
unrelated to clinicopathological variables of cancer.
Introduction
Endometrial cancer is one of the most frequently occurring
gynecological malignancies in the Western World, and its
incidence has increased significantly during the last decade
in Poland (1). In general, clinicopathological, immunohisto-
chemical, biochemical and molecular genetic analyses have
provided valuable information for dividing ECs into two dif-
ferent subtypes, estrogen-dependent (type I) and estrogen-
independent (type II) (2-4). Factors associated with unopposed
estrogenic stimulation and the presence of hyperplastic endo-
metrial lesions (concomitant with neoplasia) are linked with
the most common type of carcinoma, endometrioid-type I
tumor (5-6). On the other hand, USC and clear cell carcinoma
of the endometrium, which are not linked to estrogenic stimu-
lation and are not associated with endometrial hyperplasia,
are considered type II tumors (5,6). These sub-types differ
not only in clinicoprognostical features but also in various
molecular genetic alterations detected in oncogenes, tumor
suppressor genes and mismatch-repair genes (5). For example,
pRb1-cyclin D1-cdk4/6-p16INK4A pathway alterations were
described in endometrioid-type ECs whereas they were
uncommon in USCs in humans (7).
Mitochondria play important roles in cell homeostasis,
actively participating in energy metabolism, generation of
reactive oxygen species, aging and initiation of programmed
cell death (8,9). Mitochondrial failure has been described at
all levels of structure and function, including abnormal ultra-
structure, metabolic deregulation and genetic alterations (10).
In general, mtDNA point mutations, gene deletions and mtMSI
have been reported in human neoplasms and cell lines, but
the frequency of these alterations differs in various tumors
(11-13). The most well-known disorders caused by mtDNA
mutations are LHON (Leber's Hereditary Optic Neuropathy),
MELAS (Mitochondrial Encephalopathy, Lactic Acidosis
and Stroke-like episodes), MERRF (Myoclonic Epilepsy with
Ragged Red Fibers), maternally-inherited diabetes mellitus
and maternally inherited cardiomyopathy (10).
Data have accumulated concerning somatic mtDNA
mutations and mitochondrial microsatellite instability in
various gynecologic malignancies in humans (11). Liu et al
(14) detected a high (60%) incidence of mtDNA mutations
by sequencing DNAs isolated from malignant ovarian tissues.
Somatic D-loop mitochondrial DNA mutations were detected
at high frequency in uterine serous carcinomas extracted
from paraffin-embedded slides (15). Moreover, Wang et al
(16) reported that about 25.4% of cervical carcinomas, 48.4%
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of endometrial cancers, and 21.9% of ovarian carcinomas
carried one or more mtMSI. Our group has also analyzed
mtDNA mutations in various tumors, including human ECs
(17). However, to the best of our knowledge, there are no data
assessing the relationship, if any, between somatic mtDNA
mutations and clinicoprognostical features of women
affected by EC.
The aim of the current study was to investigate the
correlation between mtDNA somatic mutations and clinical
and pathological features of EC patients. Short-time follow-
up of the study group with regard to somatic mtDNA
mutations has also been evaluated.
Materials and methods
Frozen tumor tissues of the studied cases and their matched
normal tissues (including normal cervix, omentum or blood
samples) were collected during surgery in the Second Depart-
ment of Gynecology, Lublin University School of Medicine,
Lublin, Poland. Altogether, 40 tissues of endometrial cancer,
four cases of endometrial hyperplasia and one case of endo-
metrial stromal sarcoma were analyzed. Clinicopathological
features of EC patients enrolled are summarized at Table I.
The clinical stage of the disease was classified according to
the International Federation of Gynecology and Obstetrics
classification (18,19). The material was assessed micro-
scopically at the Department of Pathology, Lublin University
School of Medicine, Lublin, Poland, based on the World
Health Organization staging system (20).
High-molecular-weight DNA was isolated and mtDNA
genetic analysis was performed as described previously (17).
Briefly, a total of 1623 base-pairs (bp) of mtDNA [~10% of
mtDNA, including nucleotides 135-433 (region 1), 2986-3301
(region 2), 4981-5500 (region 3), 10390-10700 (region 4) and
12005-12386 (region 5)] were separately PCR-amplified and
screened for mtDNA genetic alterations by SSCP with silver
staining of the gels (21) (Fig. 1). The presence of bands with
variant migration patterns was confirmed by repeating PCR-
SSCP analysis. Sequencing analysis was performed on an
ABI PRISM 377 DNA sequencer (Pharmacia Biotech, Sweden)
using PCR products obtained from the original isolates as
template. All experiments with positive results were repeated
in order to obtain reproducibility of the results.
Statistical analysis was performed using Fisher's exact
probability test or ¯2 test where appropriate. Univariate
survival analysis for disease-free survival was performed
using the Kaplan-Meier method (22) and the log-rank test,
with the time of primary surgery serving as entry data. Data
were analyzed using the software Statistica for Windows
(Statsoft Inc., 1993, release 5.0). A p-value <0.05 was
considered significant.
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Table I. Clinical and pathological features of EC patients
studied for the somatic mtDNA mutations.
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aLymph nodes were dissected in 27 cases.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. SSCP analysis of PCR amplified mtDNA from 2 patients - 139
and 140; in the latter mutation C12258G was detected (17). For each patient
6 lanes are analyzed, the first three represent regions 1, 4, 2 and 5 from
normal, tumor and a 1:1 mixture of normal and tumor tissue, respectively.
Samples 4-6 are 1:1 mixtures of normal and tumor tissue samples for regions
1 and 4, 5 and 2, and 4 and 2, respectively.
Results
Study group. A total of 90 specimens (consisting of tumor and
normal tissues from the same patient) were collected and
investigated for the somatic mtDNA mutations. The mean
age of the EC patients was 59 (range 43-82) years, and most
of the cases had stage I disease (n=32; 80%) (Table I). Most
of our patients (n=36; 90%) were without evidence of
recurrence after a mean follow-up time of 32 months (range
8-53 months). There were two cases of simple non-atypical
hyperplasia, one complex non-atypical hyperplasia and one
complex atypical hyperplasia. The mean age of patients with
endometrial hyperplasia was 50 (range 48-52) years, and was
lower compared to the mean age of EC patients (59 years).
The single patient with endometrial sarcoma stromale was 39
years old and she was classified at stage I disease according
to the FIGO classification.
mtDNA mutations. The results of the screening for somatic
mtDNA point mutations are summarized in Table II. In total,
4 out of 40 (10%) EC samples carried changes of mtDNA,
and in one case (number 103) four different variations
occurred (17). Detailed data of mtDNA-positive EC patients
are shown in Table III. When clinicopathologial features of
patients with uterine cancer were analyzed, somatic mtDNA
mutations were reported both in early and in advanced-stage
endometrioid-type ECs (Table III). Patients carrying the
mtDNA mutations or the normal mtDNA sequence had
indistinguishable clinicopathological data (including age,
clinical stage, histological grade and type or depth of
myometrial infiltration). It is noteworthy that mtDNA
mutations were not detected in hyperplastic endometrial
tissue nor in ECs coexisting with hyperplasia (Tables II and
III). However, there was no significant relationship in the
distribution of mtDNA mutations between cases with and
without pre-cancerous endometrial lesions (p=0.56; Fisher
exact test).
Tumors with somatic mtDNA mutations showed con-
comitantly nuclear genome alterations (Table III). LOH at
the tumor suppressor genes RB1 and TP53 as well as p16INK4A
alterations (LOH, gene deletion) were reported in tumors with
mtDNA mutations. However, only in one case (number 103
from Table III) MIB-1 PI (23) was extremely high (90%).
The mtDNA from this patient contained four mutations (17).
Follow-up. We also calculated the disease-free survival of
EC patients regarding the presence or absence of somatic
mtDNA mutations during a short-time follow-up. No
significant difference in disease-free survival between
patients with and without mitochondrial alterations was
observed (p>0.05; log-rank test). None of the patients with
mtDNA mutations developed recurrences during a short-time
observation (Table III).
Discussion
Data have accumulated recently describing the significant
involvement of mitochondrial genomic alterations in the
process of human carcinogenesis (11-13). It is widely
accepted that mitochondrial DNA is highly susceptible to
genetic alterations because it is not protected by histones and
chromatin structures and is continuously exposed to reactive
oxygen species generated during oxidative phosphorylation
(8,28). The mtDNA alterations may be part of the neoplastic
transformation process or be the result of exposure to chemo-
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Cancer 40 4 (10)
Hyperplasia 4 -
Stromal sarcoma 1 -
Total 45 4 (9)
–––––––––––––––––––––––––––––––––––––––––––––––––
Table III. Clinicopathological features and molecular alterations of EC patients with mtDNA mutations.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
IHC
Staging Coexistence of LOHb ––––––––––––––––––––––––––––––––––––––
––––––––––– hyperplastic –––––––––– p16INK4A pRb-1 Cyclin p53 MIB-1 Overall
No.a Age FIGO WHO Myometrial Lymph node and neoplastic TP53 RB1 p16INK4A D1/cdk 4 PI mtDNA survival
(years) invasion involvement endometrium alterations (%) mutations (months)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
103 68 Ib G1 <1/2 - - + - - 2 2 0 1 90 Homo- 40
plasmic
107 43 IIIa G2 >1/2 - - - + + 1 2 2 2 10 Homo- 39
plasmic
113 59 Ib G2 <1/2 - - - - + 2 2 2 2 40 Homo- 34
plasmic
140 60 Ic G1 >1/2 - - - - - 2 2 2 2 40 Hetero- 28
plasmic
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aPatient numbers are the same as reported previously (17). bData concerning the molecular alterations have been published (23-27).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
therapeutic agents widely applied in oncology (12,29,30). In
the literature, mutations in mtDNA have been identified in
several human neoplasms and cell lines, although data assessing
the frequency and role of mtDNA alterations in gynecological
neoplasms, in ECs in particular, are limited (14-17,31-34).
Liu et al (14), who detected somatic mitochondrial DNA
mutations in 4 regions of the mitochondrial genome (16S and
12S rRNA genes, the D-loop and the cytochrome b gene),
suggest that these regions may represent a hot-spot in ovarian
tumorigenesis. A high incidence (63%) of D-loop region
mtDNA mutations in type II ECs has been recently reported
by Pejovic et al (15). Moreover, a high frequency of mito-
chondrial genome instability (89%; 25 out of 28) was detected
in ECs by Liu et al (31). One out of six (16%) endometrial
carcinomas showed mutations of the D310 mitochondrial
mononucleotide repeat (34). In the current study, somatic
mtDNA mutations were reported only in 10% (4 out of 40) of
primary ECs, a frequency significantly lower compared with
the data reported previously [25% by Liu et al (31) or 63%
by Pejovic et al (15)]. However, only approximately 10% of
mtDNA were screened for the molecular genetic alterations
in human ECs, and we suggest that the frequency of mtDNA
alterations would be higher when complete sequence analysis
of the mtDNA genome would be performed.
Interestingly, mtDNA abnormalities were not reported in
the hyperplastic endometria (n=4) nor in type I uterine
malignant tumors (carcinomas concomitant with hyperplasias;
n=8). To the best of our knowledge, mutations of mtDNA
have not been analyzed in precancerous human endometrial
lesions up to now (Medline® database). In the literature, Wang
et al (33) reported the increase of mtDNA copy number in
endometrial cancer cells compared to normal endometrial
glandular cells (p<0.001). Studying premalignant lesions from
the head and neck (n=137), Ha et al (35) showed a clear
increase in incidence of mitochondrial C-tract alterations
from benign hyperplasia (22%) to squamous carcinoma in situ
(62%; p<0.001). However, only two out of 45 gastric tumors
(including 15 adenomas) were positive for mtDNA mutations
in the non-coding regions of the gene (36). Additional studies
on a large scale need to be conducted to assess alterations of
the entire mitochondrial genome in atypical and non-atypical
simple/complex human endometrial hyperplasias.
It is widely accepted that the mitochondrial genome is
more vulnerable to oxidative base damage compared to the
nuclear genome (11,13). Due to the lack of histone protection,
most mutations occur in the coding mtDNA sequences and
therefore they are likely to have biological consequences.
The mtDNA mutations coexist with nuclear genome alter-
ations, and the mutation rate of mtDNA has been reported
to be higher compared to the frequency of nuclear DNA
alterations (37,38). Somatic mutations in mtDNA and nuclear
microsatellite instability were not associated with each other
in gastric carcinomas (39). Moreover, Richard et al (40)
showed the lack of association between mitochondrial and
nuclear mutations in human breast cancers, suggesting that
different systems are responsible for mitochondrial and genome
instability in cancer cells. Based on our own observations
as well as data from the literature, the mtDNA mutations
(heteroplasmic or homoplasmic) and nuclear genome alter-
ations are present during the development and progression
of cancer. However, nuclear genetic alterations have been
detected in type I ECs with and without mtDNA mutations
(data not shown). The interactions of mutations in the nuclear
and mitochondrial genomes in ECs are not yet understood
and require further analysis.
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